<DOC>
	<DOCNO>NCT01058343</DOCNO>
	<brief_summary>Interferon alpha ( IFNa ) involve pathogenesis systemic lupus erythematosus ( SLE ) IFNa level associate severity disease . Blocking IFNa could attractive therapeutic strategy . Active immunization IFNa kinoid ( IFN-K ) induce polyclonal antibody response . This study evaluate safety IFN-K patient mild moderate SLE . It also measure induction anti-IFNa antibody evaluate clinical impact SLE disease .</brief_summary>
	<brief_title>Safety IFNa Kinoid Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>1 . Diagnosis SLE accord current American College Rheumatology ( ACR ) criterion ( 4 11 ACR criterion ) , 2 . SLEDAI ≥4 ≤10 , 3 . Positive Antinuclear Antibodies ( ANA ) and/or Positive antidsDNA antibody 4 . Male female 18 50 year age 5 . Current immunity measles , mumps , rubella varicella , evidence positive IgG titer time screening , 6 . For subject recruit local influenza season , current vaccination seasonal influenza least 7 day prior randomization , 7 . Vaccination H1N1 influenza least 7 day prior randomization . 8 . For subject reproductive potential ( male female ) , use reliable mean contraception 9 . Written inform consent obtain subject . 1 . Any serious manifestation lupus entry , , opinion investigator likely require initiation offprotocol medication change course study particular BILAG A score , 2 . Any nonSLE manifestation likely require , investigator 's judgment , treatment highdose corticosteroid addition immunosuppressive regimen course trial , 3 . Received &gt; 20 mg/day prednisone equivalent &gt; 7 day 30 day prior screen , 4 . Currently receive receive pulse dose corticosteroid intravenous immunoglobulin ( IVIg ) within 3 month prior screen , 5 . Received cyclophosphamide within 3 month prior screen , 6 . Received monoclonal antibody 6 month prior screen , 7 . Previously receive investigational treatment direct IFNa , 8 . Received Bcell deplete therapy ( e.g . Rituximab ) within 12 month 9 . Received IV antibiotic 30 day prior screen , 10 . Significant electrocardiogram ( ECG ) abnormality , 11 . Evidence clinically significant abnormality chest Xray , opinion investigator could represent active infection , latent tuberculosis treatable manifestation lupus , 12 . Any laboratory abnormality clinically relevant 13 . History malignancy except completely excise basal cell carcinoma , 14 . Congenital immune deficiency , 15 . Positive IgM antibody titer presence negative IgG titer EpsteinBarr virus ( EBV ) cytomegalovirus ( CMV ) , 16 . Frequent recurrence oral genital herpes simplex lesion ( ≥ 6 / year ) , 17 . Episode shingle within one year screening , 18 . Human Immunodeficiency Virus ( HIV ) , hepatitis C virus ( HCV ) HBV ( HBsAg , antiHBc ab ) positive , 19 . Any current sign symptom infection entry , 20 . Administration live vaccine within 3 month prior study entry 21 . Planned use investigational nonregistered product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SLE</keyword>
</DOC>